Takeda Pharmaceutical Co Ltd - Net Worth and Insider Trading

Takeda Pharmaceutical Co Ltd Net Worth

The estimated net worth of Takeda Pharmaceutical Co Ltd is at least $166 Million dollars as of 2024-11-05. Takeda Pharmaceutical Co Ltd is the 10% Owner of Day One Biopharmaceuticals Inc and owns about 6,120,124 shares of Day One Biopharmaceuticals Inc (DAWN) stock worth over $90 Million. Takeda Pharmaceutical Co Ltd is the 10% Owner of Phathom Pharmaceuticals Inc and owns about 3,755,583 shares of Phathom Pharmaceuticals Inc (PHAT) stock worth over $70 Million. Takeda Pharmaceutical Co Ltd is also the 10% Owner of Ovid Therapeutics Inc and owns about 5,750,000 shares of Ovid Therapeutics Inc (OVID) stock worth over $7 Million. Details can be seen in Takeda Pharmaceutical Co Ltd's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Takeda Pharmaceutical Co Ltd has not made any transactions after 2024-01-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Takeda Pharmaceutical Co Ltd owns 14 companies in total, including Translate Bio Inc (TBIO) , BiomX Inc (PHGE.U) , and Phathom Pharmaceuticals Inc (PHAT) among others .

Click here to see the complete history of Takeda Pharmaceutical Co Ltd’s form 4 insider trades.

Insider Ownership Summary of Takeda Pharmaceutical Co Ltd

Ticker	Comapny	Transaction Date	Type of Owner
TBIO	Translate Bio Inc	2020-06-30	10 percent owner
PHGE.U	BiomX Inc	2019-10-28	10 percent owner
PHAT	Phathom Pharmaceuticals Inc	2024-01-24	10 percent owner
		2019-10-08	10 percent owner
		2019-07-17	10 percent owner
		2019-05-08	10 percent owner
		2018-03-19	10 percent owner
		2017-08-01	10 percent owner
		2021-10-18	10 percent owner
		2019-10-28	10 percent owner
		2021-10-06	10 percent owner
		2021-10-21	10 percent owner
		2021-12-08	10 percent owner
		2022-04-28	10 percent owner

Takeda Pharmaceutical Co Ltd Latest Holdings Summary

Takeda Pharmaceutical Co Ltd currently owns a total of 3 stocks. Among these stocks, Takeda Pharmaceutical Co Ltd owns 6,120,124 shares of Day One Biopharmaceuticals Inc (DAWN) as of December 8, 2021, with a value of $90 Million and a weighting of 53.92%. Takeda Pharmaceutical Co Ltd owns 3,755,583 shares of Phathom Pharmaceuticals Inc (PHAT) as of January 24, 2024, with a value of $70 Million and a weighting of 42.07%. Takeda Pharmaceutical Co Ltd also owns 5,750,000 shares of Ovid Therapeutics Inc (OVID) as of October 8, 2019, with a value of $7 Million and a weighting of 4.01%.

Latest Holdings of Takeda Pharmaceutical Co Ltd

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
DAWN	Day One Biopharmaceuticals Inc	2021-12-08	6,120,124	14.66	89,721,018
PHAT	Phathom Pharmaceuticals Inc	2024-01-24	3,755,583	18.64	70,004,067
OVID	Ovid Therapeutics Inc	2019-10-08	5,750,000	1.16	6,670,000

Holding Weightings of Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd Form 4 Trading Tracker

According to the SEC Form 4 filings, Takeda Pharmaceutical Co Ltd has made a total of 2 transactions in Day One Biopharmaceuticals Inc (DAWN) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Day One Biopharmaceuticals Inc is the sale of 297,273 shares on December 8, 2021, which brought Takeda Pharmaceutical Co Ltd around $5 Million.

According to the SEC Form 4 filings, Takeda Pharmaceutical Co Ltd has made a total of 20 transactions in Phathom Pharmaceuticals Inc (PHAT) over the past 5 years, including 0 buys and 20 sells. The most-recent trade in Phathom Pharmaceuticals Inc is the sale of 3,703,703 shares on January 24, 2024, which brought Takeda Pharmaceutical Co Ltd around $30 Million.

According to the SEC Form 4 filings, Takeda Pharmaceutical Co Ltd has made a total of 0 transactions in Ovid Therapeutics Inc (OVID) over the past 5 years. The most-recent trade in Ovid Therapeutics Inc is the acquisition of 2,000,000 shares on October 8, 2019, which cost Takeda Pharmaceutical Co Ltd around $5 Million.

Insider Trading History of Takeda Pharmaceutical Co Ltd

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Takeda Pharmaceutical Co Ltd Trading Performance

GuruFocus tracks the stock performance after each of Takeda Pharmaceutical Co Ltd's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Takeda Pharmaceutical Co Ltd is 65.16%. GuruFocus also compares Takeda Pharmaceutical Co Ltd's trading performance to market benchmark return within the same time period. The performance of stocks bought by Takeda Pharmaceutical Co Ltd within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Takeda Pharmaceutical Co Ltd's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Takeda Pharmaceutical Co Ltd

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	4.51
Relative Return to S&P 500(%)	-2.4

Takeda Pharmaceutical Co Ltd Ownership Network

Ownership Network List of Takeda Pharmaceutical Co Ltd

No Data

Ownership Network Relation of Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd Owned Company Details

What does Translate Bio Inc do?

Who are the key executives at Translate Bio Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Translate Bio Inc. Other key executives at Translate Bio Inc include director & Chief Executive Officer & other: President Renaud Ronald C Jr , Chief Operating Officer & CLO & other: Secretary Paul D. Burgess , and 10 percent owner Shire Human Genetic Therapies, Inc. .

Translate Bio Inc (TBIO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Translate Bio Inc (TBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Translate Bio Inc (TBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Translate Bio Inc (TBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Translate Bio Inc Insider Transactions

No Available Data

What does BiomX Inc do?

Who are the key executives at BiomX Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of BiomX Inc. Other key executives at BiomX Inc include 10 percent owner Kerry Propper , 10 percent owner Mountain Wood Llc , and director & 10 percent owner Erez Chimovits .

BiomX Inc (PHGE.U) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BiomX Inc (PHGE.U) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BiomX Inc (PHGE.U) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BiomX Inc (PHGE.U)'s detailed insider trading history can be found in Insider Trading Tracker table.

BiomX Inc Insider Transactions

No Available Data

What does Phathom Pharmaceuticals Inc do?

Who are the key executives at Phathom Pharmaceuticals Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Phathom Pharmaceuticals Inc. Other key executives at Phathom Pharmaceuticals Inc include CFO and CBO Molly Henderson , Chief Operating Officer Azmi Nabulsi , and director & President & CEO & Treas. & Sec. David A Socks .

Phathom Pharmaceuticals Inc (PHAT) Insider Trades Summary

Over the past 18 months, Takeda Pharmaceutical Co Ltd made 1 insider transaction in Phathom Pharmaceuticals Inc (PHAT) with a net sale of 3,703,703. Other recent insider transactions involving Phathom Pharmaceuticals Inc (PHAT) include a net sale of 32,756 shares made by Molly Henderson , a net sale of 50,699 shares made by Terrie Curran , and a net sale of 10,901 shares made by Azmi Nabulsi .

In summary, during the past 3 months, insiders sold 0 shares of Phathom Pharmaceuticals Inc (PHAT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,798,059 shares of Phathom Pharmaceuticals Inc (PHAT) were sold and 7,500 shares were bought by its insiders, resulting in a net sale of 3,790,559 shares.

Phathom Pharmaceuticals Inc (PHAT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Phathom Pharmaceuticals Inc Insider Transactions

No Available Data

What does Ovid Therapeutics Inc do?

Who are the key executives at Ovid Therapeutics Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Ovid Therapeutics Inc. Other key executives at Ovid Therapeutics Inc include director & 10 percent owner & CEO Jeremy M Levin , Chief Commercial Officer Jason Tardio , and 10 percent owner Takeda Pharmaceuticals U.s.a., Inc. .

Ovid Therapeutics Inc (OVID) Insider Trades Summary

Over the past 18 months, Takeda Pharmaceutical Co Ltd made no insider transaction in Ovid Therapeutics Inc (OVID). Other recent insider transactions involving Ovid Therapeutics Inc (OVID) include a net purchase of 18,248 shares made by Jeremy M Levin ,

In summary, during the past 3 months, insiders sold 0 shares of Ovid Therapeutics Inc (OVID) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ovid Therapeutics Inc (OVID) were sold and 18,248 shares were bought by its insiders, resulting in a net purchase of 18,248 shares.

Ovid Therapeutics Inc (OVID)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ovid Therapeutics Inc Insider Transactions

No Available Data

What does Mirum Pharmaceuticals Inc do?

Who are the key executives at Mirum Pharmaceuticals Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Mirum Pharmaceuticals Inc. Other key executives at Mirum Pharmaceuticals Inc include director & 10 percent owner Patrick J Heron , SVP & Global Controller Jolanda Howe , and Chief Scientific Officer Pamela Vig .

Mirum Pharmaceuticals Inc (MIRM) Insider Trades Summary

Over the past 18 months, Takeda Pharmaceutical Co Ltd made no insider transaction in Mirum Pharmaceuticals Inc (MIRM). Other recent insider transactions involving Mirum Pharmaceuticals Inc (MIRM) include a net purchase of 162,308 shares made by Patrick J Heron , a net sale of 8,512 shares made by Jolanda Howe , and a net sale of 34,606 shares made by Pamela Vig .

In summary, during the past 3 months, insiders sold 0 shares of Mirum Pharmaceuticals Inc (MIRM) in total and bought 345 shares, with a net purchase of 345 shares. During the past 18 months, 105,850 shares of Mirum Pharmaceuticals Inc (MIRM) were sold and 176,308 shares were bought by its insiders, resulting in a net purchase of 70,458 shares.

Mirum Pharmaceuticals Inc (MIRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mirum Pharmaceuticals Inc Insider Transactions

No Available Data

What does Quince Therapeutics Inc do?

Who are the key executives at Quince Therapeutics Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Quince Therapeutics Inc. Other key executives at Quince Therapeutics Inc include director & Chief Executive Officer Dirk Thye , Chief Business Officer Brendan Hannah , and President Charles S. Ryan .

Quince Therapeutics Inc (QNCX) Insider Trades Summary

Over the past 18 months, Takeda Pharmaceutical Co Ltd made no insider transaction in Quince Therapeutics Inc (QNCX). Other recent insider transactions involving Quince Therapeutics Inc (QNCX) include a net purchase of 500,436 shares made by David Lamond , a net purchase of 322,500 shares made by Dirk Thye , and a net purchase of 110,686 shares made by Brendan Hannah .

In summary, during the past 3 months, insiders sold 0 shares of Quince Therapeutics Inc (QNCX) in total and bought 241,811 shares, with a net purchase of 241,811 shares. During the past 18 months, 0 shares of Quince Therapeutics Inc (QNCX) were sold and 990,009 shares were bought by its insiders, resulting in a net purchase of 990,009 shares.

Quince Therapeutics Inc (QNCX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Quince Therapeutics Inc Insider Transactions

No Available Data

What does Myovant Sciences Ltd do?

Who are the key executives at Myovant Sciences Ltd?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Myovant Sciences Ltd. Other key executives at Myovant Sciences Ltd include 10 percent owner Sumitomo Chemical Co., Ltd. , Chief Commercial Officer Lauren Merendino , and General Counsel & Corp. Secy. Matthew Lang .

Myovant Sciences Ltd (MYOV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Myovant Sciences Ltd (MYOV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Myovant Sciences Ltd (MYOV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Myovant Sciences Ltd (MYOV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Myovant Sciences Ltd Insider Transactions

No Available Data

What does Molecular Templates Inc do?

Who are the key executives at Molecular Templates Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Molecular Templates Inc. Other key executives at Molecular Templates Inc include 10 percent owner Biotech Target N V , Chief Medical Officer Maurizio Voi , and CFO & Treasurer Sean Mclennan .

Molecular Templates Inc (MTEM) Insider Trades Summary

Over the past 18 months, Takeda Pharmaceutical Co Ltd made no insider transaction in Molecular Templates Inc (MTEM). Other recent insider transactions involving Molecular Templates Inc (MTEM) include a net purchase of 4,505,319 shares made by Biotech Target N V ,

In summary, during the past 3 months, insiders sold 0 shares of Molecular Templates Inc (MTEM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Molecular Templates Inc (MTEM) were sold and 533,688 shares were bought by its insiders, resulting in a net purchase of 533,688 shares.

Molecular Templates Inc (MTEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Molecular Templates Inc Insider Transactions

No Available Data

What does Calithera Biosciences Inc do?

Who are the key executives at Calithera Biosciences Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Calithera Biosciences Inc. Other key executives at Calithera Biosciences Inc include director & 10 percent owner Deepika Pakianathan , 10 percent owner Takeda Ventures, Inc. , and SR. VP & CLINICAL DEVELOPMENT Keith Orford .

Calithera Biosciences Inc (CALA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Calithera Biosciences Inc (CALA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Calithera Biosciences Inc (CALA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Calithera Biosciences Inc (CALA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Calithera Biosciences Inc Insider Transactions

No Available Data

What does BiomX Inc do?

Who are the key executives at BiomX Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of BiomX Inc. Other key executives at BiomX Inc include director & 10 percent owner Orbimed Israel Biofund Gp Limited Partnership , Chief Business Officer Assaf Oron , and 10 percent owner Carl L Gordon .

BiomX Inc (PHGE) Insider Trades Summary

Over the past 18 months, Takeda Pharmaceutical Co Ltd made no insider transaction in BiomX Inc (PHGE). Other recent insider transactions involving BiomX Inc (PHGE) include a net sale of 0 shares made by Assaf Oron , and a net sale of 24,344 shares made by Orbimed Israel Biofund Gp Limited Partnership .

In summary, during the past 3 months, insiders sold 0 shares of BiomX Inc (PHGE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,526 shares of BiomX Inc (PHGE) were sold and 1,091 shares were bought by its insiders, resulting in a net sale of 2,434 shares.

BiomX Inc (PHGE)'s detailed insider trading history can be found in Insider Trading Tracker table.

BiomX Inc Insider Transactions

No Available Data

What does Theseus Pharmaceuticals Inc do?

Who are the key executives at Theseus Pharmaceuticals Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Theseus Pharmaceuticals Inc. Other key executives at Theseus Pharmaceuticals Inc include director & 10 percent owner Carl L Gordon , director & 10 percent owner Orbimed Advisors Llc , and 10 percent owner Foresite Capital Fund V, L.p. .

Theseus Pharmaceuticals Inc (THRX) Insider Trades Summary

Over the past 18 months, Takeda Pharmaceutical Co Ltd made no insider transaction in Theseus Pharmaceuticals Inc (THRX). Other recent insider transactions involving Theseus Pharmaceuticals Inc (THRX) include a net purchase of 700,000 shares made by Foresite Capital Fund V, L.p. , a net purchase of 479,932 shares made by Orbimed Advisors Llc , and a net purchase of 479,932 shares made by Carl L Gordon .

In summary, during the past 3 months, insiders sold 0 shares of Theseus Pharmaceuticals Inc (THRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Theseus Pharmaceuticals Inc (THRX) were sold and 1,659,864 shares were bought by its insiders, resulting in a net purchase of 1,659,864 shares.

Theseus Pharmaceuticals Inc (THRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Theseus Pharmaceuticals Inc Insider Transactions

No Available Data

What does Xilio Therapeutics Inc do?

Who are the key executives at Xilio Therapeutics Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Xilio Therapeutics Inc. Other key executives at Xilio Therapeutics Inc include 10 percent owner Atlas Venture Fund Xi, L.p. , Chief Medical Officer Katarina Luptakova , and Chief Operating Officer Christopher James Frankenfield .

Xilio Therapeutics Inc (XLO) Insider Trades Summary

Over the past 18 months, Takeda Pharmaceutical Co Ltd made no insider transaction in Xilio Therapeutics Inc (XLO). Other recent insider transactions involving Xilio Therapeutics Inc (XLO) include a net sale of 5,235 shares made by Atlas Venture Fund Xi, L.p. , and a net purchase of 485,250 shares made by Gilead Sciences Inc .

In summary, during the past 3 months, insiders sold 0 shares of Xilio Therapeutics Inc (XLO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 5,235 shares of Xilio Therapeutics Inc (XLO) were sold and 485,250 shares were bought by its insiders, resulting in a net purchase of 480,015 shares.

Xilio Therapeutics Inc (XLO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Xilio Therapeutics Inc Insider Transactions

No Available Data

What does Day One Biopharmaceuticals Inc do?

Who are the key executives at Day One Biopharmaceuticals Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of Day One Biopharmaceuticals Inc. Other key executives at Day One Biopharmaceuticals Inc include Chief Medical Officer Samuel C. Blackman , COO & CFO and Secretary York Charles N Ii , and director & Chief Executive Officer Jeremy Bender .

Day One Biopharmaceuticals Inc (DAWN) Insider Trades Summary

Over the past 18 months, Takeda Pharmaceutical Co Ltd made no insider transaction in Day One Biopharmaceuticals Inc (DAWN). Other recent insider transactions involving Day One Biopharmaceuticals Inc (DAWN) include a net sale of 170,555 shares made by Samuel C. Blackman , a net sale of 114,587 shares made by Jeremy Bender , and a net sale of 71,268 shares made by York Charles N Ii .

In summary, during the past 3 months, insiders sold 49,248 shares of Day One Biopharmaceuticals Inc (DAWN) in total and bought 0 shares, with a net sale of 49,248 shares. During the past 18 months, 381,420 shares of Day One Biopharmaceuticals Inc (DAWN) were sold and 2,244,684 shares were bought by its insiders, resulting in a net purchase of 1,863,264 shares.

Day One Biopharmaceuticals Inc (DAWN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Day One Biopharmaceuticals Inc Insider Transactions

No Available Data

What does HilleVax Inc do?

Who are the key executives at HilleVax Inc?

Takeda Pharmaceutical Co Ltd is the 10 percent owner of HilleVax Inc. Other key executives at HilleVax Inc include director & Chief Operating Officer Aditya Kohli , 10 percent owner Frazier Life Sciences X, L.p. , and director & President and CEO Robert Hershberg .

HilleVax Inc (HLVX) Insider Trades Summary

Over the past 18 months, Takeda Pharmaceutical Co Ltd made no insider transaction in HilleVax Inc (HLVX). Other recent insider transactions involving HilleVax Inc (HLVX) include a net sale of 111,764 shares made by Aditya Kohli , a net sale of 48,933 shares made by Astrid Borkowski , and a net sale of 11,597 shares made by Robert Hershberg .

In summary, during the past 3 months, insiders sold 0 shares of HilleVax Inc (HLVX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 175,870 shares of HilleVax Inc (HLVX) were sold and 10,100 shares were bought by its insiders, resulting in a net sale of 165,770 shares.

HilleVax Inc (HLVX)'s detailed insider trading history can be found in Insider Trading Tracker table.

HilleVax Inc Insider Transactions

No Available Data

Takeda Pharmaceutical Co Ltd Mailing Address

Above is the net worth, insider trading, and ownership report for Takeda Pharmaceutical Co Ltd. You might contact Takeda Pharmaceutical Co Ltd via mailing address: 1-1, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo M0 103-8668.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.